Arvinas, Inc. (ARVN)
ARVNNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$6.76
+0.3500 (+5.46%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $442.68m
- P/E
- –
- EPS, last 4 quarters
- $-0.2400
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.38 to $14.51
- Average volume
- 832.0k
- Previous close
- $6.41
Analysts
11 coveringHold6 buy, 5 hold, 0 sell
Targets a year out average $14.22, +110.4% from here
Earnings
next estimate $-0.6700Next report
Dec 2025
-100.0%
Mar 2026
+5.3%
Jun 2026
+1175.0%
Sep 2026
-2.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $9.50m | $15.60m | $249.70m | $500.0k |
| Gross profit | $9.50m | $15.60m | $240.70m | $400.0k |
| Operating income | -$74.60m | -$63.80m | $164.10m | -$59.10m |
| Net income | -$67.40m | -$57.60m | $169.40m | -$53.90m |
Last four quarters: revenue $275.30m, margin -3.5%, free cash flow -$159.80m
News
8 latest- Arvinas (ARVN) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- What Arvinas (ARVN) Said on Its Q3 Earnings CallMarketBeat · 6 days ago
- Arvinas, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateFintel · 6 days ago
- Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue EstimatesZacks · 7 days ago
- Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?Zacks · Oct 19, 2026
- Roche Gets FDA Approval for Enspryng in Thyroid Eye DiseaseZacks · Oct 16, 2026
- KRYS Reports Positive Early Data for KB113 in Gorlin SyndromeZacks · Oct 16, 2026
- Reasons Why Investors Should Consider Betting on Arvinas StockZacks · Oct 13, 2026
The company
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA) approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- arvinas.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.